Thrombotic thrombocytopenic purpura and autoimmunity: A tale of shadows and suspects

Haematologica

Volumn 84, Issue 3, 1999, Pages 260-269

  Porta, Camillo ^a   Caporali, Roberto ^a   Montecucco, Carlomaurizio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Autoimmunity; Thrombotic thrombocytopenic purpura

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PENICILLAMINE;

ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; HUMORAL IMMUNITY; PATHOGENESIS; STEROID THERAPY; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0032856965     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (107)

1. Moschkowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924; 24:21-4.
2. Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura. Hemorrhagic diathesis with generalized platelet thromboses. Blood 1947; 2:542-4.
3. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura. Medicine 1981; 60:413-28.
4. Torok TJ, Holman RC, Chorbat L. Increasing mortality from thrombotic thrombocytopenic purpura in the United States: analysis of national mortality data 1968-1991. Am J Hematol 1995; 50:84-90.
5. Bobbio-Pallavicini E, Porta C, Fornasari PM, Viarengo GL, Ascari E. Thrombotic thrombocytopenic purpura (TTP): retrospective study on 84 patients and therapeutical prospects. Transfus Sci 1992; 13:39-44.
6. Murphy WG, Moore JC, Warkentin TE, Hayward EP, Kelton JG. Thrombotic thrombocytopenic purpura. Blood Coagul Fibrinolysis 1992; 3:655-9.
7. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma-exchange with plasma-infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325:393-7.
8. Rose M, Rowe JM, Eldor A. The changing course of thrombotic thrombocytopenic purpura and modern therapy. Blood Rev 1993; 7:94-103.
9. Murphy WG, Moore JC, Kelton JG. Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpura. Blood 1987; 70:1683-7.
10. Falanga A, Consonni R, Ruggenenti P, Barbui T. A cathepsin-like proteinase activity in thrombotic thrombocytopenic purpura. Br J Haematol 1991; 79:474-80.
11. Consonni R, Falanga A, Barbui T. Further characterization of platelet-aggregating cysteine proteinase activity in thrombotic thrombocytopenic purpura. Br J Haematol 1994;87:321-4.
12. Kelton JG, Moore JC, Warkentin TE, Hayward CP. Isolation and characterization of cysteine proteinase in thrombotic thrombocytopenic purpura. Br J Haematol 1996; 93:421-6.
13. Moake JL. Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Semin Hematol 1997; 34:83-9.
14. Remuzzi G, Imberti L, De Gaetano G. Prostacyclin deficiency in thrombotic microangiopathies. Lancet 1981; 2:1422-3.
15. Kwaan HC. Role of fibrinolysis in thrombotic thrombocytopenic purpura. Semin Hematol 1987; 24:71-81.
16. Wada H, Kaneko T, Ohiwa M, et al. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol 1993; 44:101-5.
17. Laurence J, Mitra D, Steiner M, Staiano-Coico L, Jaffe E. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood 1996; 87:3245-57.
18. Neame PB. Immunologic and other factors in thrombotic thrombocytopenic purpura (TTP). Semin Thromb Hemost 1980; 6:416-29.
19. Centurioni R, Bobbio-Pallavicini E, Porta C, et al. Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins. Results in 17 patients. Haematologica 1995; 80:325-31.
20. Burns ER, Zucker-Franklin D. Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood 1982; 60:1030-7.
21. Leung DY, Moake JL, Havens PL, Kim M, Pober JS. Lytic anti-endothelial cell antibodies in haemolyticuraemic syndrome. Lancet 1988; 23:183-6.
22. Koenig DW, Barley-Maloney L, Daniel TO. A Western blot assay detects autoantibodies to cryptic endothelial antigens in thrombotic microangiopathies. J Clin Immunol 1993; 13:204-11.
23. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 1994; 88:816-25.
24. Gorini M, Luliri P. Steroids: what role in TTP? Transfus Sci 1992;13:73-6.
25. Bobbio-Pallavicini E, Porta C, Centurioni R, et al. Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. Eur J Haematol 1994; 52:222-6.
26. Bird JM, Cummins D, Machin SJ. Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura [letter]. Lancet 1990; i:565-6.
27. Moake JL, Rudy CK, Troll JH, et al. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. Am J Hematol 1985; 20:73-9.
28. Fessler BJ. Thrombotic syndromes and autoimmune diseases. Rheum Dis Clin N Am 1997; 23:461-79.
29. Esmon NL, Smirnov MD, Esmon CT. Lupus anticoagulant and thrombosis: the role of phospholipids. Haematologica 1997; 82:474-7.
30. Khamashta MA, Hughes GRV. Antiphospholipid antibodies and antiphospholipid syndrome. Curr Opin Rheumatol 1995; 7:389-94.
31. Del Papa N, Guidali L, Sala A, et al. Endothelial cells as the target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta2-glycoprotein-1 antibodies react in vitro with endothelial cells through adherent β2-glycoprotein-1 and induce endothelial activation. Arthritis Rheum 1997; 40:551-61.
32. Del Papa N, Raschi E, Catelli L, et al. Endothelial cells as target for antiphospholipid antibodies: role of anti-β2-glycoprotein-1 antibodies. Am J Reprod Immunol 1997; 38:212-7.
33. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1880; 87:4120-4.
34. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994; 84:2854-67.
35. Osoting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, De Groot PG. Antiphospholipid antibodies directed against a combination of phospholipid with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81:2618-25.
36. Shi W, Chong BH, Chesterman CN. β2-glycoprotein I is a requirement for anticardiolipin antibody binding to activated platelets: differences with lupus anticoagulants. Blood 1993; 81:1255-62.
37. Arvieux J, Roussel B, Pouzol P, Colomb MG. Platelet activating properties of murine monoclonal antibodies to β2-glycoprotein I. Thromb Haemost 1993; 70: 336-41.
38. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelism with heparin-induced thrombocytopenia. Thromb Haemost 1996; 75:536-41.
39. Vane JR, Botting RM. Endothelium-thromboresistance. Wien Klin Wochenschr 1991; 103:403-4.
40. Vanhoutte PM, Eber B. Endothelial-derived relaxing and contracting factors. Wien Klin Wochenschr 1991; 103:405-11.
41. Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB. The role of nitric oxide in the pathogenesis of preeclampsia. Am J Obstet Gynecol 1994; 171:944-8.
42. Porta C, Buggia I, Bonomi I, Caporali R, Scatola C, Montecucco C. Nitrite and nitrate plasma levels, as markers of nitric oxide synthesis, in antiphospholipid antibodies-related conditions and in thrombotic thrombocytopenic purpura [letter]. Thromb Haemost 1997; 78:965-7.
43. Porta C, Buggia I, Bonomi I, et al. Nitrite and nitrate plasma levels, as markers for nitric oxide synthesis, in thrombotic thrombocytopenic purpura (TTP). A case-control study. Hematology 1996; 1:239-46.
44. Montecucco C, Di Lauro M, Bobbio-Pallavicini E, et al. Anti-phospholipid antibodies and thrombotic thrombocytopenic purpura. Clin Exp Rheumatol 1987; 5:355-8.
45. Caporali R, Choucair J, Bobbio-Pallavicini E, Porta C, Montecucco C. Autoantibody profile in thrombotic thrombocytopenic purpura. Transfus Sci 1992; 13:33-6.
46. Jain R, Chartash E, Susin M, Furie R. Systemic lupus erythematosus and thrombotic microangiopathies. Semin Arthritis Rheum 1994; 24:173-82.
47. Itoh Y, Sekine H, Hosono O, et al. Thrombotic thrombocytopenic purpura in two patients with systemic lupus erythematosus: clinical significance of anti-platelet antibodies. Clin Immunol Immunopathol 1990; 57:125-36.
48. Huang JJ, Chen MW, Sung JM, Lan RR, Wang MC, Chen FF. Post-partum hemolytic uraemic syndrome associated with antiphospholipid antibody. Nephrol Dial Transplant 1998; 13:182-6.
49. Montecucco C, Longhi M, Caporali R, De Gennaro F. Hematological abnormalities associated with anticardiolipin antibodies. Haematologica 1989; 74:195-204.
50. nd ed. Philadelphia, Lippincott-Raven, 1996. p. 211-24.
51. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991; 21:55-64.
52. Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988; 23:380-4.
53. Porta C, Bobbio-Pallavicini E, Centurioni R, Tacconi F, Caporali R, Montecucco CM. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus [letter]. J Rheumatol 1993; 20:1625-6.
54. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica 1997; 82:429-35.
55. Fox DA, Faix JD, Coblyn J, Fraser P, Smith B, Weinblatt ME. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Ann Rheum Dis 1986; 45:319-22.
56. Gordon LI, Kwaan HC. Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997; 34:140-7.
57. Antman K, Skarin A, Mayer R. Microangiopathic hemolytic anemia and cancer: a review. Medicine 1979; 58:377-84.
58. Forsyth KD, Simpson A, Fitzpatrick MM, Barratt TM, Levinsky RJ. Neutrophil-mediated endothelial injury in hemolytic-uremic syndrome. Lancet 1989; i:411-4.
59. Bolande RP, Kaplan BS. Experimental studies on the hemolytic-uremic syndrome. Nephron 1985; 39:228-36.
60. Millford D, Taylor CM, Rafaat F, Halloran E, Dawes J. Neutrophil elastases and haemolytic-uraemic syndrome [letter]. Lancet 1989; ii:1153.
61. Rollino C, Roccatello D, Menegatti E, Piccoli G. Antineutrophil cytoplasm and antielastase antibodies in hemolytic-uremic syndrome [letter], Nephron 1993; 65:320-1.
62. Porta C, Caporali R, Montecucco C, Bobbio-Pallavicini E on behalf of the Italian Cooperative Group for TTP. Lack of evidence of antineutrophil cytoplasmic antibodies involvement in the acute phase of thrombotic thrombocytopenic purpura [letter]. Nephron 1996; 73:352-3.
63. Olavarria F, Mezzano S, Valderrama G. Detection of antineutrophil cytoplasmic antibodies in the classic form of hemolytic uremic syndrome [letter]. Nephron 1994; 66:235.
64. Miles JL. Value of test for antineutrophil cytoplasmic antibodies in the diagnosis and treatment of vasculitis. Curr Opin Rheumatol 1993; 5:18-24.
65. Montecucco C. Role of ANCA in the pathogenesis of Wegener's granulomatosis: a short review. Monaldi Arch Chest Dis 1994; 49:323-6.
66. Moses J, Lichtman SM, Brody J, Wisch N, Moake JL. Hairy cell leukemia in association with thrombotic thrombocytopenic purpura and factor VIII antibodies. Leuk Lymphoma 1996; 22:351-4.
67. Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990; 65:2237-42.
68. Dvorak HF, Gresser I. Microvascular injury in the pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989; 81:497-502.
69. Tada T, Kishimoto H. An autopsy case of thrombotic thrombocytopenic purpura (TTP) complicated with systemic lupus erythematosus (SLE) - demonstration of anti-platelet antibody. Rinsho Ketsueki 1980; 21: 1773-80.
70. Bodensteiner D, Rosenfeld C. Elevated platelet-surface-bound IgM in thrombotic thrombocytopenic purpura. South Med J 1988; 81:81-3.
71. Nakajima T, Koyama T, Kakishita E, Nagai K. Inhibitory effects of TTP sera on binding of anti-platelet glycoprotein IIb-IIIa monoclonal antibodies to human vascular endothelial cells. Am J Hematol 1987; 25: 115-8.
72. Stein RS, Flexner JM. Persistently perplexing purpuras: thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura [letter]. Ann Intern Med 1994; 121:720-1.
73. Krupsky M, Saral R, Hurwitz N, Resnitzky P. Late appearance of thrombotic thrombocytopenic purpura after autoimmune hemolytic anemia and in the course of chronic autoimmune chrombocytopenic purpura: two case reports. Acta Haematol 1991; 85: 139-42.
74. Routy JP, Beaulieu R, Monte M, Saint-Louis J, Sauvageau G, Toma E. Immunologic thrombocytopenic purpura followed by thrombotic thrombocytopenic purpura in two HIV1 patients. Am J Hematol 1991; 38:327-8.
75. Majado MJ, Gonzalez C, Candal R. Thrombotic thrombocytopenic purpura after immune thrombocytopenic purpura [letter]. Sangre (Barc) 1993; 38: 504-5.
76. Olenich M, Schattner E. Postpartum thrombotic thrombocytopenic purpura (TTP) complicating pregnancy-associated immune thrombocytopenic purpura. Ann Intern Med 1994; 120:845-7.
77. Yospur LS, Sun NC, Figueroa P, Niihara Y. Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in a HIV-positive patient: case-report and review of the literature. Am J Hematol 1996; 51:73-8.
78. Zucker-Franklin D, Karpatkin S. Red-cell and platelet fragmentation in idiopathic autoimmune thrombocytopenic purpura. N Engl J Med 1977; 297:517-23.
79. Zucker-Franklin D. Persistently perplexing purpuras: thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura [letter]. Ann Intern Med 1994; 121:721.
80. Macchi L, Rispal P, Clofent-Sanchez G, et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid syndrome: their relationship with the observed thrombocytopenia. Br J Haematol 1997; 98:336-41.
81. Creenwalt DE, Lipsky RH, Ockenhouse CF, Ikeda H, Tandon NN, Jamieson GA. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction and transfusion medicine. Blood 1992; 80: 1105-15.
82. Daviet L, McGregor JL. Vascular biology of CD36: roles ofthis new adhesion molecule family in different disease states. Thromb Haemost 1997; 78:65-9.
83. Knowles DM, Tolidjian B, Marboe C, et al. Monoclonal anti-human monocyte antibodies OKM1 and OKM5 possess distinctive tissue distributions including differential reactivity with vascular endothelium. J Immunol 1984; 132:2170-3.
84. Swerlick RA, Lee KH, Wick TM, Lawley TJ. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 1992; 148:78-83.
85. Aiken ML, Ginsberg MH, Byers-Ward V, Plow RF. Effects of OKM5, a monoclonal antibody to glycoprotein IV, on the platelet aggregation and thrombospondin surface expression. Blood 1990; 76:2501-9.
86. Lian ECY, Siddiqui FA, Jamieson GA, Tandon NN. Platelet agglutinating protein p37 causes platelet agglutination through its binding to membrane glycoprotein IV. Thromb Haemost 1991; 65:102-6.
87. Siddiqui FA, Lian ECY. Platelet-agglutinating protein p37 from a thrombotic thrombocytopenic purpura plasma forms complexes with platelet membrane glycoprotein IV(CD36). Biochem Int 1992; 27:485-96.
88. Siddiqui FA, Lian ECY. Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma. J Clin Invest 1985; 76:1330-7.
89. Lian ECY, Siddiqui FA. Binding of platelet agglutinating protein p37 from the plasma of a patient with thrombotic thrombocytopenic purpura to human platelets. Thromb Haemost 1991; 65:96-101.
90. Rock G, Chauhan K, Jamieson GA, Tandon NN. Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. Br J Haematol 1994; 88:878-80.
91. Al-Shahi R, Mason JC, Rao R, et al. Systemic lupus erythematosus, thrombocytopenia, microangiopathic haemolytic anaemia and anti-CD36 antibodies. Br J Rheumatol 1997; 36:794-8.
92. Borzini P, Riva M, Nembri P, et al. CD36 autoantibodies and thrombotic diathesis, thrombocytopenia and repeated early fetal losses. Vox Sang 1997; 73:46-8.
93. Tsai HM, Nagel RL, Hatcher VB, Sussman II. Multimers composition of endothelial cell-derived von Willebrand factor. Blood 1989; 73:2074-6.
94. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willenbrand factor. Proc Natl Acad Sci USA 1990; 87:6306-10 [Erratum, Proc Natl Acad Sci USA 1990; 87:9508].
95. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994; 83:2171-9.
96. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factorto fragments produced by in vivo proteolysis. Blood 1996; 97:4223-34.
97. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-44.
98. Furlan M, Robles M, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89:3097-103.
99. Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91:2839-46.
100. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578-84.
101. Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
102. Moake JL. Moschcowitz, multimers and metalloprotease [editorial]. N Engl J Med 1998; 339:1629-31.
103. Bettendorf U, Potters R. Moschcowitz's disease following D-penicillamine medication. Med Welt 1975; 26:291-5.
104. Speth PA, Boerboons AM, Holdrinet RS, Van de Putte LB, Meyer JW. Thrombotic thrombocytopenic purpura associated with D-penicillamine treatment in rheumatoid arthritis. J Rheumatol 1982; 9:812-3.
105. Trice JM, Finals RS, Plitman GI. Thrombotic thrombocytopenic purpura during penicillamine therapy in rheumatoid arthritis. Arch Intern Med 1983; 143:1487-8.
106. Ahmed F, Sumalnop V, Spain DM, Tobin MS. Thrombotic thrombocytopenic purpura during penicillamine therapy. Arch Intern Med 1978; 138:1292-3.
107. Harrison EE, Hickman JW. Hemolytic anemia and thrombocytopenia associated with D-penicillamine therapy. Southern Med J 1975; 68:113-5.